| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors
|
Patnaik, Amita
|
|
2014
|
73 |
5 |
p. 951-960
|
artikel
|
| 2 |
A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer
|
Chan, S.
|
|
2014
|
73 |
5 |
p. 903-910
|
artikel
|
| 3 |
A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma
|
Arrieta, Oscar
|
|
2014
|
73 |
5 |
p. 975-982
|
artikel
|
| 4 |
A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
|
Shoji, Tadahiro
|
|
2014
|
73 |
5 |
p. 895-901
|
artikel
|
| 5 |
A phase I study of oral ixabepilone in patients with advanced solid tumors
|
Deeken, John F.
|
|
2014
|
73 |
5 |
p. 1071-1078
|
artikel
|
| 6 |
Apoptosis and KI 67 index correlate with preoperative chemotherapy efficacy and better predict the survival of gastric cancer patients with combined therapy
|
Wu, Aiwen
|
|
2014
|
73 |
5 |
p. 885-893
|
artikel
|
| 7 |
Asparaginase in the treatment of non-ALL hematologic malignancies
|
Emadi, Ashkan
|
|
2014
|
73 |
5 |
p. 875-883
|
artikel
|
| 8 |
Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer
|
Younis, Islam R.
|
|
2014
|
73 |
5 |
p. 991-997
|
artikel
|
| 9 |
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis
|
Aoyama, Toru
|
|
2014
|
73 |
5 |
p. 1047-1054
|
artikel
|
| 10 |
DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development
|
Shah, Eric D.
|
|
2014
|
73 |
5 |
p. 1089-1093
|
artikel
|
| 11 |
DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development
|
Shah, Eric D.
|
|
|
73 |
5 |
p. 1089-1093
|
artikel
|
| 12 |
Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience
|
Kato, Yuka
|
|
2014
|
73 |
5 |
p. 943-950
|
artikel
|
| 13 |
Folates provoke cellular efflux and drug resistance of substrates of the multidrug resistance protein 1 (MRP1)
|
Hooijberg, Jan Hendrik
|
|
2014
|
73 |
5 |
p. 911-917
|
artikel
|
| 14 |
Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma
|
Thiery-Vuillemin, A.
|
|
2014
|
73 |
5 |
p. 999-1007
|
artikel
|
| 15 |
Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression
|
Maffezzini, Massimo
|
|
2014
|
73 |
5 |
p. 925-930
|
artikel
|
| 16 |
Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
|
Lee, Ji Yun
|
|
2014
|
73 |
5 |
p. 1063-1070
|
artikel
|
| 17 |
Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer
|
Hasegawa, Junichi
|
|
2014
|
73 |
5 |
p. 1079-1087
|
artikel
|
| 18 |
No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers
|
Chen, Nianhang.
|
|
2014
|
73 |
5 |
p. 1031-1039
|
artikel
|
| 19 |
Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors
|
Curtis, Kelly K.
|
|
2014
|
73 |
5 |
p. 931-941
|
artikel
|
| 20 |
Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure
|
Lee, Suh-Young
|
|
2014
|
73 |
5 |
p. 1021-1029
|
artikel
|
| 21 |
Pharmacokinetics, placenta, and brain uptake of paclitaxel in pregnant rats
|
Lee, Na-Young
|
|
2014
|
73 |
5 |
p. 1041-1045
|
artikel
|
| 22 |
Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102
|
Fidler, John M.
|
|
2014
|
73 |
5 |
p. 961-974
|
artikel
|
| 23 |
Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients
|
Pérez-Ruixo, Carlos
|
|
2014
|
73 |
5 |
p. 1009-1020
|
artikel
|
| 24 |
Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy
|
Simó, Marta
|
|
2014
|
73 |
5 |
p. 919-923
|
artikel
|
| 25 |
The impact of 5-formyltetrahydrofolate on the anti-tumor activity of pralatrexate, as compared to methotrexate, in HeLa cells in vitro
|
Visentin, Michele
|
|
2014
|
73 |
5 |
p. 1055-1062
|
artikel
|
| 26 |
The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation
|
Hong, Xin
|
|
2014
|
73 |
5 |
p. 983-990
|
artikel
|
Tijdschrift beschrijving